This CME-accredited activity “Multiple Myeloma & Lymphoma Summit” features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to, CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
TARGET AUDIENCE
- Cancer care professionals
- Practicing medical oncologists/hematologists
- Radiation oncologists
- Pathologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
LEARNING OBJECTIVES
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for induction, autologous transplantation, and maintenance therapy for patients with newly diagnosed multiple myeloma
- Outline efficacy and toxicities of monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with relapsed and refractory multiple myeloma
- Review CAR-T, bispecific antibodies, and antibody drug conjugates in management of DLBCL patients
- Apply an individualized treatment plan for patients with early/advanced stage cHL and T cell lymphomas
- List indications and toxicity profile of novel targeted agents in management of indolent lymphomas including CLL, FL, MCL
- Review the indications for the treatment of Waldenström Macroglobulinemia and current therapeutic strategies
VENUE:
DoubleTree by Hilton Park City – The Yarrow